The single-cell genome sequencing-based cancer market is rapidly expanding, driven by advancements in genomic technologies, rising cancer prevalence, and growing demand for personalized treatments. Single-cell genome sequencing has primarily been utilized in cancer research to examine critical factors such as intra-tumor heterogeneity, clonal evolution, invasion and metastasis, circulating tumor cells, and treatment response. These applications are contributing to substantial market expansion, especially in the fields of personalized cancer therapies and cutting-edge diagnostic solutions.
Ongoing innovations in sequencing technologies, such as improved throughput, accuracy, and cost-effectiveness, are making single-cell sequencing more accessible and efficient. New platforms, such as 10x Genomics' Chromium, PacBio's Onso, and Illumina’s NovaSeq, are pushing the boundaries of what can be achieved with single-cell analysis, supporting applications in cancer diagnostics, biomarker discovery, and drug development. Organizations such as the National Cancer Institute (NCI) and World Health Organization (WHO) are funding research projects that utilize single-cell sequencing technologies to uncover new insights into cancer biology, driving demand for cutting-edge sequencing tools.
